Clinical Trials Browser

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05382299 2026-04-06

ASCENT-03

Phase 3 Active not recruiting

623 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02445391 2026-04-01

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Phase 3 Active not recruiting

415 enrolled 15 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06519370 2026-01-22

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Phase 3 Active not recruiting

350 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03997123 2025-12-22

CAPItello-290

Phase 3 Active not recruiting

923 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05347134 2025-12-09

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Phase 3 Active not recruiting

254 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04595565 2025-11-25

SASCIA

Phase 3 Active not recruiting

1,332 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06382142 2025-11-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 3 Active not recruiting

418 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05382286 2025-09-18

ASCENT-04

Phase 3 Active not recruiting

443 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

325 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04915755 2025-07-16

ZEST

Phase 3 Active not recruiting

40 enrolled 13 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03562637 2025-05-09

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Phase 3 Active not recruiting

575 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03168880 2025-04-09

TNBC

Phase 3 Active not recruiting

720 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04296175 2025-03-26

CITRINE

Phase 3 Active not recruiting

808 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02488967 2024-06-03

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Phase 3 Active not recruiting

782 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03281954 2024-04-08

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Phase 3 Active not recruiting

1,550 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

ASCENT-03

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

CAPItello-290

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

SASCIA

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

ASCENT-04

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

ZEST

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

TNBC

CITRINE

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo